{"id":4044,"date":"2026-10-18T16:32:17","date_gmt":"2026-10-18T20:32:17","guid":{"rendered":"https:\/\/canasanta.ca\/?p=4044"},"modified":"2026-10-18T17:10:20","modified_gmt":"2026-10-18T21:10:20","slug":"farmaco-experimental-anb033-celiaquia-gluten-intestino","status":"publish","type":"post","link":"https:\/\/canasanta.ca\/en\/salud\/farmaco-experimental-anb033-celiaquia-gluten-intestino\/","title":{"rendered":"Un f\u00e1rmaco experimental protege el intestino frente al gluten en un ensayo sobre celiaqu\u00eda"},"content":{"rendered":"

Un anticuerpo experimental logr\u00f3 proteger la mucosa intestinal y reducir los s\u00edntomas provocados por una exposici\u00f3n intensa al gluten en un peque\u00f1o ensayo cl\u00ednico aleatorizado con personas cel\u00edacas. Los resultados son prometedores, pero todav\u00eda son preliminares: ANB033 no est\u00e1 aprobado y el estudio evalu\u00f3 solo 32 participantes que completaron el desaf\u00edo con gluten.<\/h3>\n

La celiaqu\u00eda obliga hoy a mantener una dieta estrictamente libre de gluten. Incluso exposiciones accidentales pueden reactivar la respuesta inmunitaria, producir dolor, diarrea, hinchaz\u00f3n y volver a lesionar las vellosidades del intestino delgado. Por eso el resultado comunicado por First Tracks Biotherapeutics merece atenci\u00f3n: apunta a la posibilidad de a\u00f1adir, en el futuro, una protecci\u00f3n farmacol\u00f3gica a la dieta.<\/p>\n

<\/div>\n

Dos semanas comiendo el equivalente a dos rebanadas de pan al d\u00eda<\/strong><\/h2>\n

El estudio de fase 1b fue aleatorizado y controlado con placebo. Los participantes recibieron tres dosis subcut\u00e1neas de ANB033 o placebo en las semanas 0, 2 y 4. Despu\u00e9s fueron sometidos durante 14 d\u00edas a un desaf\u00edo de 6 gramos diarios de gluten, aproximadamente el equivalente a dos rebanadas de pan.<\/p>\n

En el an\u00e1lisis de eficacia, 17 pacientes recibieron ANB033 y 15 placebo. Los investigadores midieron tanto s\u00edntomas como cambios microsc\u00f3picos en el intestino, entre ellos la relaci\u00f3n entre la altura de las vellosidades y la profundidad de las criptas, y la densidad de linfocitos intraepiteliales, dos indicadores utilizados para cuantificar el da\u00f1o cel\u00edaco.<\/p>\n

<\/div>\n

La diferencia apareci\u00f3 dentro del intestino<\/strong><\/h2>\n

Tras el desaf\u00edo con gluten, la relaci\u00f3n vellosidad-cripta cay\u00f3 0,66 puntos en el grupo placebo frente a 0,17 en el grupo tratado. La diferencia ajustada fue de 0,49 puntos y alcanz\u00f3 significaci\u00f3n estad\u00edstica (p=0,009).<\/p>\n

La densidad de linfocitos intraepiteliales aument\u00f3 18,83 puntos con placebo, mientras que disminuy\u00f3 1,20 puntos entre quienes recibieron ANB033. La diferencia ajustada entre ambos grupos fue de 20,03 puntos (p<0,001). En otras palabras, bajo las condiciones controladas del ensayo, el medicamento evit\u00f3 buena parte de la respuesta inflamatoria que normalmente desencadena el gluten.<\/p>\n

<\/div>\n

Tambi\u00e9n hubo menos s\u00edntomas<\/strong><\/h2>\n

Los pacientes registraron diariamente dolor abdominal, hinchaz\u00f3n, n\u00e1useas, diarrea y cansancio mediante el Celiac Disease Symptom Diary. El grupo tratado mantuvo puntuaciones inferiores al placebo durante el desaf\u00edo. Adem\u00e1s, el 47% de los pacientes que recibieron placebo necesit\u00f3 medicaci\u00f3n permitida para aliviar s\u00edntomas gastrointestinales, frente al 6% de quienes recibieron ANB033.<\/p>\n

La compa\u00f1\u00eda inform\u00f3 que no se observaron eventos adversos graves ni se\u00f1ales de seguridad importantes en esta cohorte. Eso no equivale a demostrar seguridad a largo plazo: la muestra fue peque\u00f1a y el seguimiento todav\u00eda es limitado.<\/p>\n

<\/div>\n

C\u00f3mo intenta funcionar ANB033<\/strong><\/h2>\n

ANB033 es un anticuerpo experimental dirigido contra CD122, la subunidad beta compartida por los receptores de las interleucinas IL-15 e IL-2. Ambas se\u00f1ales participan en la activaci\u00f3n de c\u00e9lulas inmunitarias implicadas en la inflamaci\u00f3n intestinal de la celiaqu\u00eda. Bloquear simult\u00e1neamente esas rutas busca reducir la agresi\u00f3n inmunol\u00f3gica sin depender \u00fanicamente de evitar el gluten.<\/p>\n

La estrategia es particularmente interesante porque intenta actuar sobre el mecanismo inmunitario de la enfermedad y no solo sobre sus s\u00edntomas. Sin embargo, los datos proceden de resultados preliminares comunicados por la propia compa\u00f1\u00eda y a\u00fan deben confirmarse en estudios mayores y en fases cl\u00ednicas posteriores.<\/p>\n

<\/div>\n

Lo que todav\u00eda falta demostrar<\/strong><\/h2>\n

Esta primera cohorte no demuestra que una persona cel\u00edaca pueda abandonar la dieta sin gluten. Tampoco establece que ANB033 prevenga complicaciones a largo plazo. El ensayo fue dise\u00f1ado como una prueba controlada de exposici\u00f3n al gluten y cont\u00f3 con pocas decenas de participantes.<\/p>\n

Una segunda cohorte est\u00e1 evaluando si el tratamiento puede favorecer la reparaci\u00f3n de la mucosa intestinal durante 12 semanas en pacientes con distintos grados de da\u00f1o y s\u00edntomas. La compa\u00f1\u00eda prev\u00e9 resultados de esa parte del estudio en 2027 y planea avanzar el programa hacia etapas cl\u00ednicas posteriores.<\/p>\n

La se\u00f1al inicial, no obstante, es dif\u00edcil de ignorar: por primera vez este anticuerpo experimental mostr\u00f3 simult\u00e1neamente protecci\u00f3n histol\u00f3gica y reducci\u00f3n de s\u00edntomas frente a una exposici\u00f3n deliberada al gluten. Si ensayos m\u00e1s grandes reproducen el efecto y confirman su seguridad, la celiaqu\u00eda podr\u00eda acercarse a algo que hoy no tiene: una terapia farmacol\u00f3gica capaz de proteger el intestino adem\u00e1s de la dieta.<\/p>","protected":false},"excerpt":{"rendered":"

Un peque\u00f1o ensayo cl\u00ednico de fase 1b encontr\u00f3 que ANB033 redujo el da\u00f1o intestinal y los s\u00edntomas durante una exposici\u00f3n controlada al gluten en pacientes con celiaqu\u00eda.<\/p>","protected":false},"author":284226809,"featured_media":4045,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_wpcom_ai_launchpad_first_post":false,"_jetpack_hide_featured_image":false,"_jetpack_featured_image_duplicate_dismissed":0,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[33205457,2127],"tags":[33207045,33207043,33207047,33207046,33207044],"class_list":["post-4044","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-al-dia","category-salud","tag-anb033","tag-celiaquia","tag-enfermedades-autoinmunes","tag-ensayos-clinicos","tag-gluten"],"acf":[],"yoast_head":"\nUn f\u00e1rmaco experimental protege el intestino frente al gluten en un ensayo sobre celiaqu\u00eda - Ca\u00f1asanta<\/title>\n<meta name=\"description\" content=\"ANB033 protegi\u00f3 la mucosa intestinal y redujo s\u00edntomas durante un desaf\u00edo con gluten en un ensayo fase 1b con pacientes cel\u00edacos.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/canasanta.ca\/en\/health\/farmaco-experimental-anb033-celiaquia-gluten-intestino\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Un f\u00e1rmaco experimental protege el intestino frente al gluten en un ensayo sobre celiaqu\u00eda\" \/>\n<meta property=\"og:description\" content=\"ANB033 protegi\u00f3 la mucosa intestinal y redujo s\u00edntomas durante un desaf\u00edo con gluten en un ensayo fase 1b con pacientes cel\u00edacos.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/canasanta.ca\/en\/health\/farmaco-experimental-anb033-celiaquia-gluten-intestino\/\" \/>\n<meta property=\"og:site_name\" content=\"Ca\u00f1asanta\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-18T20:32:17+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-18T21:10:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Gluten-y-celiaquia-\u2014-portada-Canasanta.jpg?resize=1200,630&quality=85&strip=all&ssl=1\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Ca\u00f1asanta\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Ca\u00f1asanta\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/canasanta.ca\\\/salud\\\/farmaco-experimental-anb033-celiaquia-gluten-intestino\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/canasanta.ca\\\/salud\\\/farmaco-experimental-anb033-celiaquia-gluten-intestino\\\/\"},\"author\":{\"name\":\"Ca\u00f1asanta\",\"@id\":\"https:\\\/\\\/canasanta.ca\\\/#\\\/schema\\\/person\\\/21421a3c6f1733be6c5c590190fd8e93\"},\"headline\":\"Un f\u00e1rmaco experimental protege el intestino frente al gluten en un ensayo sobre celiaqu\u00eda\",\"datePublished\":\"2026-10-18T20:32:17+00:00\",\"dateModified\":\"2026-10-18T21:10:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/canasanta.ca\\\/salud\\\/farmaco-experimental-anb033-celiaquia-gluten-intestino\\\/\"},\"wordCount\":750,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/canasanta.ca\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/canasanta.ca\\\/salud\\\/farmaco-experimental-anb033-celiaquia-gluten-intestino\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/i0.wp.com\\\/canasanta.ca\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/Gluten-y-celiaquia-%E2%80%94-portada-Canasanta.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1\",\"keywords\":[\"ANB033\",\"celiaqu\u00eda\",\"enfermedades autoinmunes\",\"ensayos cl\u00ednicos\",\"gluten\"],\"articleSection\":[\"AL D\u00cdA!\",\"Salud\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/canasanta.ca\\\/salud\\\/farmaco-experimental-anb033-celiaquia-gluten-intestino\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/canasanta.ca\\\/salud\\\/farmaco-experimental-anb033-celiaquia-gluten-intestino\\\/\",\"url\":\"https:\\\/\\\/canasanta.ca\\\/salud\\\/farmaco-experimental-anb033-celiaquia-gluten-intestino\\\/\",\"name\":\"Un f\u00e1rmaco experimental protege el intestino frente al gluten en un ensayo sobre celiaqu\u00eda - Ca\u00f1asanta\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/canasanta.ca\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/canasanta.ca\\\/salud\\\/farmaco-experimental-anb033-celiaquia-gluten-intestino\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/canasanta.ca\\\/salud\\\/farmaco-experimental-anb033-celiaquia-gluten-intestino\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/i0.wp.com\\\/canasanta.ca\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/Gluten-y-celiaquia-%E2%80%94-portada-Canasanta.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1\",\"datePublished\":\"2026-10-18T20:32:17+00:00\",\"dateModified\":\"2026-10-18T21:10:20+00:00\",\"description\":\"ANB033 protegi\u00f3 la mucosa intestinal y redujo s\u00edntomas durante un desaf\u00edo con gluten en un ensayo fase 1b con pacientes cel\u00edacos.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/canasanta.ca\\\/salud\\\/farmaco-experimental-anb033-celiaquia-gluten-intestino\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/canasanta.ca\\\/salud\\\/farmaco-experimental-anb033-celiaquia-gluten-intestino\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/canasanta.ca\\\/salud\\\/farmaco-experimental-anb033-celiaquia-gluten-intestino\\\/#primaryimage\",\"url\":\"https:\\\/\\\/i0.wp.com\\\/canasanta.ca\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/Gluten-y-celiaquia-%E2%80%94-portada-Canasanta.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1\",\"contentUrl\":\"https:\\\/\\\/i0.wp.com\\\/canasanta.ca\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/Gluten-y-celiaquia-%E2%80%94-portada-Canasanta.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1\",\"width\":1200,\"height\":630,\"caption\":\"Pan de trigo sobre una tabla, imagen editorial para un art\u00edculo sobre celiaqu\u00eda y un tratamiento experimental\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/canasanta.ca\\\/salud\\\/farmaco-experimental-anb033-celiaquia-gluten-intestino\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/canasanta.ca\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Salud\",\"item\":\"https:\\\/\\\/canasanta.ca\\\/category\\\/salud\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Un f\u00e1rmaco experimental protege el intestino frente al gluten en un ensayo sobre celiaqu\u00eda\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/canasanta.ca\\\/#website\",\"url\":\"https:\\\/\\\/canasanta.ca\\\/\",\"name\":\"Ca\u00f1asanta\",\"description\":\"Magazine\",\"publisher\":{\"@id\":\"https:\\\/\\\/canasanta.ca\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/canasanta.ca\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/canasanta.ca\\\/#organization\",\"name\":\"Ca\u00f1asanta\",\"url\":\"https:\\\/\\\/canasanta.ca\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/canasanta.ca\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/i0.wp.com\\\/canasanta.ca\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/LOGO_CS.jpg?fit=1500%2C500&quality=82&strip=all&ssl=1\",\"contentUrl\":\"https:\\\/\\\/i0.wp.com\\\/canasanta.ca\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/LOGO_CS.jpg?fit=1500%2C500&quality=82&strip=all&ssl=1\",\"width\":1500,\"height\":500,\"caption\":\"Ca\u00f1asanta\"},\"image\":{\"@id\":\"https:\\\/\\\/canasanta.ca\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/canasanta.ca\\\/#\\\/schema\\\/person\\\/21421a3c6f1733be6c5c590190fd8e93\",\"name\":\"Ca\u00f1asanta\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/925594ac8e278f26e2e7403182642a1af3a9d1885cb6168deb61adb801ffd2b3?s=96&d=identicon&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/925594ac8e278f26e2e7403182642a1af3a9d1885cb6168deb61adb801ffd2b3?s=96&d=identicon&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/925594ac8e278f26e2e7403182642a1af3a9d1885cb6168deb61adb801ffd2b3?s=96&d=identicon&r=g\",\"caption\":\"Ca\u00f1asanta\"},\"sameAs\":[\"http:\\\/\\\/canasantaonline-pbuqn.wordpress.com\"],\"url\":\"https:\\\/\\\/canasanta.ca\\\/en\\\/author\\\/canasantaonline\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Un f\u00e1rmaco experimental protege el intestino frente al gluten en un ensayo sobre celiaqu\u00eda - Ca\u00f1asanta","description":"ANB033 protegi\u00f3 la mucosa intestinal y redujo s\u00edntomas durante un desaf\u00edo con gluten en un ensayo fase 1b con pacientes cel\u00edacos.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/canasanta.ca\/en\/health\/farmaco-experimental-anb033-celiaquia-gluten-intestino\/","og_locale":"en_US","og_type":"article","og_title":"Un f\u00e1rmaco experimental protege el intestino frente al gluten en un ensayo sobre celiaqu\u00eda","og_description":"ANB033 protegi\u00f3 la mucosa intestinal y redujo s\u00edntomas durante un desaf\u00edo con gluten en un ensayo fase 1b con pacientes cel\u00edacos.","og_url":"https:\/\/canasanta.ca\/en\/health\/farmaco-experimental-anb033-celiaquia-gluten-intestino\/","og_site_name":"Ca\u00f1asanta","article_published_time":"2026-10-18T20:32:17+00:00","article_modified_time":"2026-10-18T21:10:20+00:00","og_image":[{"width":1200,"height":630,"url":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Gluten-y-celiaquia-\u2014-portada-Canasanta.jpg?resize=1200,630&quality=85&strip=all&ssl=1","type":"image\/jpeg"}],"author":"Ca\u00f1asanta","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Ca\u00f1asanta","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/canasanta.ca\/salud\/farmaco-experimental-anb033-celiaquia-gluten-intestino\/#article","isPartOf":{"@id":"https:\/\/canasanta.ca\/salud\/farmaco-experimental-anb033-celiaquia-gluten-intestino\/"},"author":{"name":"Ca\u00f1asanta","@id":"https:\/\/canasanta.ca\/#\/schema\/person\/21421a3c6f1733be6c5c590190fd8e93"},"headline":"Un f\u00e1rmaco experimental protege el intestino frente al gluten en un ensayo sobre celiaqu\u00eda","datePublished":"2026-10-18T20:32:17+00:00","dateModified":"2026-10-18T21:10:20+00:00","mainEntityOfPage":{"@id":"https:\/\/canasanta.ca\/salud\/farmaco-experimental-anb033-celiaquia-gluten-intestino\/"},"wordCount":750,"commentCount":0,"publisher":{"@id":"https:\/\/canasanta.ca\/#organization"},"image":{"@id":"https:\/\/canasanta.ca\/salud\/farmaco-experimental-anb033-celiaquia-gluten-intestino\/#primaryimage"},"thumbnailUrl":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Gluten-y-celiaquia-%E2%80%94-portada-Canasanta.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1","keywords":["ANB033","celiaqu\u00eda","enfermedades autoinmunes","ensayos cl\u00ednicos","gluten"],"articleSection":["AL D\u00cdA!","Salud"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/canasanta.ca\/salud\/farmaco-experimental-anb033-celiaquia-gluten-intestino\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/canasanta.ca\/salud\/farmaco-experimental-anb033-celiaquia-gluten-intestino\/","url":"https:\/\/canasanta.ca\/salud\/farmaco-experimental-anb033-celiaquia-gluten-intestino\/","name":"Un f\u00e1rmaco experimental protege el intestino frente al gluten en un ensayo sobre celiaqu\u00eda - Ca\u00f1asanta","isPartOf":{"@id":"https:\/\/canasanta.ca\/#website"},"primaryImageOfPage":{"@id":"https:\/\/canasanta.ca\/salud\/farmaco-experimental-anb033-celiaquia-gluten-intestino\/#primaryimage"},"image":{"@id":"https:\/\/canasanta.ca\/salud\/farmaco-experimental-anb033-celiaquia-gluten-intestino\/#primaryimage"},"thumbnailUrl":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Gluten-y-celiaquia-%E2%80%94-portada-Canasanta.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1","datePublished":"2026-10-18T20:32:17+00:00","dateModified":"2026-10-18T21:10:20+00:00","description":"ANB033 protegi\u00f3 la mucosa intestinal y redujo s\u00edntomas durante un desaf\u00edo con gluten en un ensayo fase 1b con pacientes cel\u00edacos.","breadcrumb":{"@id":"https:\/\/canasanta.ca\/salud\/farmaco-experimental-anb033-celiaquia-gluten-intestino\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/canasanta.ca\/salud\/farmaco-experimental-anb033-celiaquia-gluten-intestino\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/canasanta.ca\/salud\/farmaco-experimental-anb033-celiaquia-gluten-intestino\/#primaryimage","url":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Gluten-y-celiaquia-%E2%80%94-portada-Canasanta.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1","contentUrl":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Gluten-y-celiaquia-%E2%80%94-portada-Canasanta.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1","width":1200,"height":630,"caption":"Pan de trigo sobre una tabla, imagen editorial para un art\u00edculo sobre celiaqu\u00eda y un tratamiento experimental"},{"@type":"BreadcrumbList","@id":"https:\/\/canasanta.ca\/salud\/farmaco-experimental-anb033-celiaquia-gluten-intestino\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/canasanta.ca\/"},{"@type":"ListItem","position":2,"name":"Salud","item":"https:\/\/canasanta.ca\/category\/salud\/"},{"@type":"ListItem","position":3,"name":"Un f\u00e1rmaco experimental protege el intestino frente al gluten en un ensayo sobre celiaqu\u00eda"}]},{"@type":"WebSite","@id":"https:\/\/canasanta.ca\/#website","url":"https:\/\/canasanta.ca\/","name":"Ca\u00f1asanta","description":"Magazine","publisher":{"@id":"https:\/\/canasanta.ca\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/canasanta.ca\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/canasanta.ca\/#organization","name":"Ca\u00f1asanta","url":"https:\/\/canasanta.ca\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/canasanta.ca\/#\/schema\/logo\/image\/","url":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/LOGO_CS.jpg?fit=1500%2C500&quality=82&strip=all&ssl=1","contentUrl":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/LOGO_CS.jpg?fit=1500%2C500&quality=82&strip=all&ssl=1","width":1500,"height":500,"caption":"Ca\u00f1asanta"},"image":{"@id":"https:\/\/canasanta.ca\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/canasanta.ca\/#\/schema\/person\/21421a3c6f1733be6c5c590190fd8e93","name":"Ca\u00f1asanta","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/925594ac8e278f26e2e7403182642a1af3a9d1885cb6168deb61adb801ffd2b3?s=96&d=identicon&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/925594ac8e278f26e2e7403182642a1af3a9d1885cb6168deb61adb801ffd2b3?s=96&d=identicon&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/925594ac8e278f26e2e7403182642a1af3a9d1885cb6168deb61adb801ffd2b3?s=96&d=identicon&r=g","caption":"Ca\u00f1asanta"},"sameAs":["http:\/\/canasantaonline-pbuqn.wordpress.com"],"url":"https:\/\/canasanta.ca\/en\/author\/canasantaonline\/"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/phoxY0-13e","jetpack-related-posts":[{"id":4330,"url":"https:\/\/canasanta.ca\/en\/salud\/una-pildora-experimental-de-gilead-logra-respuesta-clinica-en-el-66-de-pacientes-con-colitis-ulcerosa\/","url_meta":{"origin":4044,"position":0},"title":"Una p\u00edldora experimental de Gilead logra respuesta cl\u00ednica en el 66% de pacientes con colitis ulcerosa","author":"Ca\u00f1asanta","date":"October 19, 2026","format":false,"excerpt":"Emvistegrast, una terapia oral experimental de Gilead, alcanz\u00f3 respuesta cl\u00ednica en el 66% de los pacientes con colitis ulcerosa moderada o grave frente al 37% con placebo en un ensayo de fase 2.","rel":"","context":"In "AL D\u00cdA!"","block_context":{"text":"AL D\u00cdA!","link":"https:\/\/canasanta.ca\/en\/category\/al-dia\/"},"img":{"alt_text":"Medicamentos en una investigaci\u00f3n cl\u00ednica sobre colitis ulcerosa","src":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Emvistegrast-y-colitis-ulcerosa.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Emvistegrast-y-colitis-ulcerosa.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Emvistegrast-y-colitis-ulcerosa.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Emvistegrast-y-colitis-ulcerosa.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=700%2C400 2x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Emvistegrast-y-colitis-ulcerosa.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=1050%2C600 3x"},"classes":[]},{"id":4843,"url":"https:\/\/canasanta.ca\/en\/salud\/pildora-experimental-reduce-recaidas-esclerosis-multiple\/","url_meta":{"origin":4044,"position":1},"title":"Una p\u00edldora experimental reduce un 55% las reca\u00eddas de esclerosis m\u00faltiple","author":"Ca\u00f1asanta","date":"October 21, 2026","format":false,"excerpt":"Fenebrutinib, el tratamiento oral experimental de Roche, redujo un 55% las reca\u00eddas de esclerosis m\u00faltiple en ensayos de fase avanzada y mostr\u00f3 efectos sobre la progresi\u00f3n de la enfermedad.","rel":"","context":"In "AL D\u00cdA!"","block_context":{"text":"AL D\u00cdA!","link":"https:\/\/canasanta.ca\/en\/category\/al-dia\/"},"img":{"alt_text":"Especialistas m\u00e9dicos examinan im\u00e1genes cerebrales durante una evaluaci\u00f3n neurol\u00f3gica","src":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Esclerosis-multiple-%E2%80%94-nuevos-resultados-de-fenebrutinib.jpg?fit=1080%2C608&quality=82&strip=all&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Esclerosis-multiple-%E2%80%94-nuevos-resultados-de-fenebrutinib.jpg?fit=1080%2C608&quality=82&strip=all&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Esclerosis-multiple-%E2%80%94-nuevos-resultados-de-fenebrutinib.jpg?fit=1080%2C608&quality=82&strip=all&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Esclerosis-multiple-%E2%80%94-nuevos-resultados-de-fenebrutinib.jpg?fit=1080%2C608&quality=82&strip=all&ssl=1&resize=700%2C400 2x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Esclerosis-multiple-%E2%80%94-nuevos-resultados-de-fenebrutinib.jpg?fit=1080%2C608&quality=82&strip=all&ssl=1&resize=1050%2C600 3x"},"classes":[]},{"id":4199,"url":"https:\/\/canasanta.ca\/en\/salud\/pildora-emvistegrast-colitis-ulcerosa-ensayo-fase-2\/","url_meta":{"origin":4044,"position":2},"title":"Una p\u00edldora experimental logra remisi\u00f3n en el 31% de pacientes con colitis ulcerosa en un ensayo","author":"Ca\u00f1asanta","date":"October 22, 2026","format":false,"excerpt":"\u00a0\u00a0Una p\u00edldora experimental de una toma diaria logr\u00f3 una respuesta cl\u00ednica significativamente mayor que el placebo en pacientes con colitis ulcerosa moderada o grave, seg\u00fan resultados de fase 2 anunciados este lunes 19 de octubre por Gilead Sciences. El f\u00e1rmaco, emvistegrast, todav\u00eda no est\u00e1 aprobado y deber\u00e1 superar ensayos de\u2026","rel":"","context":"In "AL D\u00cdA!"","block_context":{"text":"AL D\u00cdA!","link":"https:\/\/canasanta.ca\/en\/category\/al-dia\/"},"img":{"alt_text":"M\u00e9dico conversa con una paciente hospitalizada, imagen editorial para informaci\u00f3n sobre colitis ulcerosa","src":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Colitis-ulcerosa-%E2%80%94-ensayo-clinico.jpg?fit=1080%2C720&quality=82&strip=all&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Colitis-ulcerosa-%E2%80%94-ensayo-clinico.jpg?fit=1080%2C720&quality=82&strip=all&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Colitis-ulcerosa-%E2%80%94-ensayo-clinico.jpg?fit=1080%2C720&quality=82&strip=all&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Colitis-ulcerosa-%E2%80%94-ensayo-clinico.jpg?fit=1080%2C720&quality=82&strip=all&ssl=1&resize=700%2C400 2x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Colitis-ulcerosa-%E2%80%94-ensayo-clinico.jpg?fit=1080%2C720&quality=82&strip=all&ssl=1&resize=1050%2C600 3x"},"classes":[]},{"id":5394,"url":"https:\/\/canasanta.ca\/en\/salud\/farmaco-oral-johnson-johnson-tumores-prostata\/","url_meta":{"origin":4044,"position":3},"title":"UN F\u00c1RMACO ORAL HACE RETROCEDER TUMORES DE PR\u00d3STATA","author":"Ca\u00f1asanta","date":"October 24, 2026","format":false,"excerpt":"Un medicamento experimental de toma diaria desarrollado por Johnson & Johnson logr\u00f3 que tumores de pr\u00f3stata desaparecieran o redujeran su tama\u00f1o en pacientes de un ensayo cl\u00ednico en fase inicial, seg\u00fan resultados divulgados este s\u00e1bado. El avance abre una nueva v\u00eda para tratar uno de los c\u00e1nceres m\u00e1s frecuentes entre\u2026","rel":"","context":"In "AL D\u00cdA!"","block_context":{"text":"AL D\u00cdA!","link":"https:\/\/canasanta.ca\/en\/category\/al-dia\/"},"img":{"alt_text":"Medicamentos orales, imagen editorial para ensayo de c\u00e1ncer de pr\u00f3stata","src":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Farmaco-oral-experimental-contra-cancer-de-prostata.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Farmaco-oral-experimental-contra-cancer-de-prostata.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Farmaco-oral-experimental-contra-cancer-de-prostata.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Farmaco-oral-experimental-contra-cancer-de-prostata.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=700%2C400 2x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Farmaco-oral-experimental-contra-cancer-de-prostata.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=1050%2C600 3x"},"classes":[]},{"id":5649,"url":"https:\/\/canasanta.ca\/en\/salud\/novartis-borra-1900-millones-farmaco-fallido\/","url_meta":{"origin":4044,"position":4},"title":"NOVARTIS BORRA US$1.900 MILLONES TRAS FALLAR UN F\u00c1RMACO","author":"Ca\u00f1asanta","date":"October 27, 2026","format":false,"excerpt":"Novartis registra un deterioro de US$1.900 millones tras el tropiezo cl\u00ednico de del-desiran, aunque eleva sus previsiones gracias al empuje de otros medicamentos.","rel":"","context":"In "AL D\u00cdA!"","block_context":{"text":"AL D\u00cdA!","link":"https:\/\/canasanta.ca\/en\/category\/al-dia\/"},"img":{"alt_text":"Sede de Novartis en Basilea, Suiza","src":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Novartis-Basel-%E2%80%94-portada-CANASANTA-27-octubre-2026.jpg?fit=1200%2C906&quality=82&strip=all&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Novartis-Basel-%E2%80%94-portada-CANASANTA-27-octubre-2026.jpg?fit=1200%2C906&quality=82&strip=all&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Novartis-Basel-%E2%80%94-portada-CANASANTA-27-octubre-2026.jpg?fit=1200%2C906&quality=82&strip=all&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Novartis-Basel-%E2%80%94-portada-CANASANTA-27-octubre-2026.jpg?fit=1200%2C906&quality=82&strip=all&ssl=1&resize=700%2C400 2x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Novartis-Basel-%E2%80%94-portada-CANASANTA-27-octubre-2026.jpg?fit=1200%2C906&quality=82&strip=all&ssl=1&resize=1050%2C600 3x"},"classes":[]},{"id":5179,"url":"https:\/\/canasanta.ca\/en\/salud\/nuevo-farmaco-frena-59-avance-cancer-mama\/","url_meta":{"origin":4044,"position":5},"title":"NUEVO F\u00c1RMACO FRENA UN 59% EL AVANCE DEL C\u00c1NCER DE MAMA","author":"Ca\u00f1asanta","date":"October 23, 2026","format":false,"excerpt":"Un tratamiento experimental redujo un 59% el riesgo de progresi\u00f3n o muerte en una forma com\u00fan de c\u00e1ncer de mama avanzado frente a la quimioterapia.","rel":"","context":"In "AL D\u00cdA!"","block_context":{"text":"AL D\u00cdA!","link":"https:\/\/canasanta.ca\/en\/category\/al-dia\/"},"img":{"alt_text":"Investigadora observa cultivos celulares en un laboratorio oncol\u00f3gico","src":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Investigacion-cancer-de-mama-1200x630-1.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Investigacion-cancer-de-mama-1200x630-1.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Investigacion-cancer-de-mama-1200x630-1.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Investigacion-cancer-de-mama-1200x630-1.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=700%2C400 2x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Investigacion-cancer-de-mama-1200x630-1.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=1050%2C600 3x"},"classes":[]}],"jetpack_featured_media_url":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Gluten-y-celiaquia-%E2%80%94-portada-Canasanta.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1","_links":{"self":[{"href":"https:\/\/canasanta.ca\/en\/wp-json\/wp\/v2\/posts\/4044","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/canasanta.ca\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/canasanta.ca\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/canasanta.ca\/en\/wp-json\/wp\/v2\/users\/284226809"}],"replies":[{"embeddable":true,"href":"https:\/\/canasanta.ca\/en\/wp-json\/wp\/v2\/comments?post=4044"}],"version-history":[{"count":3,"href":"https:\/\/canasanta.ca\/en\/wp-json\/wp\/v2\/posts\/4044\/revisions"}],"predecessor-version":[{"id":4061,"href":"https:\/\/canasanta.ca\/en\/wp-json\/wp\/v2\/posts\/4044\/revisions\/4061"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/canasanta.ca\/en\/wp-json\/wp\/v2\/media\/4045"}],"wp:attachment":[{"href":"https:\/\/canasanta.ca\/en\/wp-json\/wp\/v2\/media?parent=4044"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/canasanta.ca\/en\/wp-json\/wp\/v2\/categories?post=4044"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/canasanta.ca\/en\/wp-json\/wp\/v2\/tags?post=4044"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}